ESR2 and neoplasm: On the other hand, some report the opposite, where increased expression of ERβ in patients receiving endocrine therapy predicted poor prognosis and significantly reduced median tumor-free survival time33 as well as lower disease-free survival (DFS) in postmenopausal primary BC patients34.